Day: May 14, 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that...

CLIAwaived, Inc. Named First Authorized Approved Distributor for Wondfo USA’s new WELLlife(TM) COVID-19/Influenza A&B POC and Home (OTC) Tests

CLIAwaived, Inc. has been named the first authorized approved distributor for Wondfo USA's innovative WELLlife™ COVID-19/Influenza A&B Point-of-Care (POC) and...

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic...

error: Content is protected !!